Bristol Myers Squibb to Participate in Upcoming Investor Conferences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Pentagon reportedly locked down, hazmat teams responding
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Bristol-Myers Squibb Co. (BMY) PT Raised to $51 at Jefferies
August 28, 2024 5:41 AM EDTJefferies analyst Akash Tewari raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $51.00 (from $49.00) while maintaining a Hold rating.
The analyst comments "Bayer will present asundexian OCEANIC-AF data at ESC (stopped due to inferior efficacy vs Eliquis). While we remain on... More
